PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Amand F. Schmidt, Lucy S. Pearce, John T. Wilkins, John P. Overington, Aroon Hingorani, Juan Pablo Casas*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: Primary To quantify the short (24 weeks), medium (one year), and long-term (five year) effects of PCSK9MABs on lipid parameters and CVD risk. Secondary To quantify the safety of PCSK9 MABs, specifically focusing on the incidence of type 2 diabetes, cognitive function, and cancer. Additionally, we will determine if treatment should be tailored to certain patient subgroups that are more or less likely to benefit from PCSK9 MABs.

Original languageEnglish (US)
Article numberCD011748
JournalCochrane Database of Systematic Reviews
Volume2015
Issue number6
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease'. Together they form a unique fingerprint.

Cite this